XML 40 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727
Basis of Presentation and Summary of Significant Accounting Policies (Details 2) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Dec. 31, 2013
Investment Concentration Risk        
Cash, cash equivalents and investments $ 398,400      
Investment in institutional money market funds 1,800      
Cash and cash equivalents 89,884 $ 202,057 $ 119,296 $ 26,986
Amount invested in a single fund $ 1,000      
Sales Revenue, Net | Customer Concentration Risk | Amerisource Bergen Drug Corporation        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer 24.00% 38.00%    
Sales Revenue, Net | Customer Concentration Risk | Takeda Pharmaceutical Company Limited        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer 24.00% 10.00%    
Sales Revenue, Net | Customer Concentration Risk | McKesson Corporation        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer 10.00% 25.00%    
Sales Revenue, Net | Customer Concentration Risk | Cardinal Health Inc        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer   17.00%    
Sales Revenue, Net | Customer Concentration Risk | Cardinal Health Inc | Maximum        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer 10.00%      
Sales Revenue, Net | Customer Concentration Risk | Group Purchasing Organization        
Customers representing 10% or more of revenues        
Percentage of revenues from major customer 24.00% 27.00%    
Sales Revenue, Net | Geographic Concentration Risk        
Percentage of revenues From customers outside of the U.S.        
Approximate percentage of revenues from customers outside the U.S. 24.00% 12.00%